RHHBY
No price yet
Announcements
Nothing here yet
Daily updates
- Roche reported new one-year Phase 3 MEERKAT and SANDCAT data showing that investigational vamikibart continued to support rapid, sustained vision improvements and reduced macular thickness in adults with uveitic macular edema compared with sham injections.Oct 10, 2026
- Roche received FDA approval for Tecentriq and Tecentriq Hybreza, combined with a fluoropyrimidine and oxaliplatin, for adjuvant treatment of stage III dMMR colon cancer.Oct 9, 2026
- Roche paid $75 million upfront for Simcere Zaiming's trispecific autoimmune and cancer drugSep 7, 2026
FDA designations
Nothing here yet
News
- Roche partners with Hansoh Pharmaceutical in a deal offering $400 million upfront and over $15 billion in potential milestones to develop antibody-drug conjugates using Hansoh's proprietary technologyOct 19, 2026
- Roche to present pivotal data from its late-stage lung and breast cancer portfolio at ESMO 2026Oct 19, 2026
- Roche signs a $1 billion deal with China's Rona Therapeutics for an RNAi obesity drug targeting visceral fatOct 18, 2026
- Genentech, a member of the Roche Group , FDA approves Genentech's Enspryng (satralizumab-mwge), the first and only at-home subcutaneous treatment option for thyroid eye disease in adultsOct 16, 2026
- Roche expands its China dealmaking with a $1 billion agreement with Rona Therapeutics for an RNAi obesity drug targeting visceral fatOct 15, 2026